Limited Reimbursement for Axillary Hyperhidrosis Treatment Market Reducing Access to Care

The global Axillary Hyperhidrosis Treatment Market was worth USD 1.43 billion in 2021, and it is expected to grow at a CAGR of 5.8% during the forecast period. The growth is fueled by several factors such as rising awareness among individuals, technological advancements, and the significant development of electronic and laser therapy. The availability of health coverage offered by private and public companies has also contributed to an increase in demand for hyperhidrosis treatments. Primary axillary hyperhidrosis is a medical condition that affects daily activities, and it is prevalent in Japan, affecting one in 20 people. However, there are limited therapeutic drugs that are indicated for the treatment of primary axillary hyperhidrosis, and these are reimbursed by insurance, hence the need for new treatment alternatives.

Request a sample Report of Axillary Hyperhidrosis Treatment Market@ https://www.reportsanddata.com/download-free-sample/2059

While sweating is essential for regulating body temperature, excessive sweating caused by various factors such as spending too much time in the sun, feeling anxious, or being ill can lead to other issues, including heat exhaustion, anxiety, and disease. There are several treatments available, including lifestyle changes, aluminum-based antiperspirants, oral medications, and clinical-grade cloth wipes, which are effective in managing excessive sweating. In severe cases, surgical methods may be required, including laser therapy, liposuction, and scraping or eliminating sweat glands. The demand for minimally invasive surgical treatments such as Endoscopic Thoracic Sympathectomy (ETS) that severs glands controlling perspiration is also increasing.

Major players in the market include:

AbbVie Inc.,
Fresh Tracks Therapeutics, Inc.,
Cynosure LLC,
Dermadry Laboratories lnc.,
Dermira, Inc.,
GSK plc,
Miramar Lab Inc.,
Sesderma,
Ulthera, Inc.,
Roivant Sciences Ltd.

Request latest Report Insights of Axillary Hyperhidrosis Treatment Market@ https://www.reportsanddata.com/request-latest-insight/2059

Driving Factors:

Rising awareness among individuals about hyperhidrosis and its treatment options.
Technological advancements in the development of electronic and laser therapy.
Increasing prevalence of primary axillary hyperhidrosis globally.
Availability of health coverage offered by private and public companies.
Limited therapeutic drugs available for the treatment of primary axillary hyperhidrosis, leading to a demand for new treatment alternatives.
Lifestyle changes leading to an increase in sweating, such as spending more time in the sun or increased exercise.
A growing number of patients seeking minimally invasive surgical treatments, such as Endoscopic Thoracic Sympathectomy (ETS).
New product launches and innovations in the Axillary Hyperhidrosis Treatment Market.

Request a Report Customization of Axillary Hyperhidrosis Treatment Market @ https://www.reportsanddata.com/request-customization-form/2059

Restraints:

High cost of hyperhidrosis treatment, including surgery, medication, and other therapeutic options, which may limit access to these treatments for some patients.
Side effects associated with hyperhidrosis treatment, which may deter patients from seeking treatment or limit the effectiveness of the treatment.
Lack of awareness and diagnosis of hyperhidrosis in certain regions, resulting in a lower demand for treatment options.
Limited reimbursement for hyperhidrosis treatment, which may discourage patients from seeking treatment due to the high out-of-pocket costs.
Stringent regulations for hyperhidrosis treatment, which may slow down the approval and commercialization process for new treatment options.
The availability of alternative treatment options, such as over-the-counter antiperspirants, which may reduce the demand for hyperhidrosis treatment.

Notable Innovations:

MiraDry: This is a non-invasive treatment that uses microwave technology to destroy sweat glands in the underarm area, reducing sweat production. The treatment is FDA-approved and offers a permanent solution to hyperhidrosis.
Ultherapy: This is a non-invasive ultrasound treatment that tightens and lifts the skin, reducing sweating in the treated area. The treatment has been used successfully to treat hyperhidrosis in the underarms, hands, and feet.
Botox: Botulinum toxin (Botox) injections are commonly used to treat hyperhidrosis. The treatment involves injecting Botox into the affected area to block the nerve signals that trigger sweat production. The treatment offers temporary relief from hyperhidrosis and is FDA-approved for use in the underarms.
Iontophoresis: This is a non-invasive treatment that involves using a low-level electric current to reduce sweating. The treatment is FDA-approved for use in the hands, feet, and underarms.
Endoscopic Thoracic Sympathectomy (ETS): This is a minimally invasive surgical procedure that severs the nerves that trigger excessive sweating. The treatment offers a permanent solution to hyperhidrosis, but it is reserved for severe cases due to the risks associated with the surgery.

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, TouchPoints, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provide our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs